No black box warning on record for Odomzo

As of the latest FDA labeling reviewed, Odomzo (SONIDEGIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Odomzo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Embryo-Fetal Toxicity: Advise patients not to donate blood or blood products during treatment with ODOMZO and for at least 20 months after the last dose. ( 5.1 ) Musculoskeletal Adverse Reactions: Obtain serum creatine kinase (CK) and creatinine levels prior to initiating therapy, periodically during treatment, and as clinically indicated. Temporary dose interruption or

No black box warning on record for Odomzo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Embryo-Fetal Toxicity: Advise patients not to donate blood or blood products during treatment with ODOMZO and for at least 20 months after the last dose. ( 5.1 ) Musculoskeletal Adverse Reactions: Obtain serum creatine kinase (CK) and creatinine levels prior to initiating therapy, periodically during treatment, and as clinically indicated. Temporary dose interruption or

Odomzo Black Box Warning

No black box warning on record for Odomzo

Other warnings & precautions

Odomzo Black Box Warning

No black box warning on record for Odomzo

Other warnings & precautions